摘要
目的探究老年前列腺增生患者服用非那雄胺后骨代谢指标及骨密度是否发生变化。方法选取2010年10月至2011年10月我院收治的老年前列腺增生患者100例,随机将其分为观察组和对照组各50例。两组患者均服用盐酸坦索罗辛,观察组患者再口服非那雄胺,对照组未服用非那雄胺,只口服安慰剂。治疗1 d后分别检测两组患者骨代谢的各项指标及骨密度情况,分别检测非那雄胺组患者用药1 d、5 d、10 d后骨代谢指标及骨密度值情况。结果两组患者治疗1 d后的血钙、血磷、血肌酐、25-OH维生素、甲状旁腺激素(PTH)、总睾酮等生化指标大致相似,差异无统计学意义(P>0.05),但治疗1 d后观察组患者的双氢睾酮水平明显低于对照组,差异具有统计学意义(P<0.05)。用药治疗1 d后,两组患者的总Ⅰ型前胶原氨基端延长肽(TP1NP)、Ⅰ型胶原羧基端肽β特殊序列(β-CTX)、N-端骨钙素(OC)等骨代谢指标及腰椎、股骨颈、股骨大转子等部位的骨密度值均较相近,差异无统计学意义(P>0.05);观察组治疗1 d、5 d、10 d后的骨代谢指标及骨密度值均大致相似,差异无统计学意义(P>0.05)。结论非那雄胺对老年前列腺增生患者的骨代谢指标及骨密度无明显影响,且引起骨质疏松的风险小。
Objective To explore the changes of bone metabolism and bone mineral density in elderly pa- tients with benign prostatic hyperplasia （BPH） after taking Finasteride. Methods One hundred patients with BPH in our hospital from October 2010 to October 2011 were randomly divided into the observation group and the control group, each with 50 cases. Patients in the observation group applied Finasteride orally based on Tamsulosin, while those in the control group took oral placebo based on Tamsulosin. The bone metabolism indicators and BMD condi- tions in the two groups were detected 1 d after treatment, and the indicators in the observation group were detected 1 d, 5 d, 10 d after treatment. Results The two groups showed no statistically significant difference in calcium, phospho- rus, creatinine, 25-0/-/vitamin, parathyroid hormone （PTH）, total testosterone and other biochemical markers 1 datter treatment （F〉O.05）, but the dihydrotestosterone levels in the observation group were significantly lower than that in the control group 1 d after treatment （P〈0.05）. The indicators of bone metabolism including type I procollagen total amino-terminal extension peptide （TP1NP）, I collagen carboxy-terminal peptide of fl special sequence （fl-CTX）, N-terminal osteocalcin （OC） and BMD values such as lumbar spine, femoral neck, trochanter values also showed no statistically significant difference between the two groups ld after treatment （P〉O.05）. The bone metabolism indicators and BMD values in the observation group showed no statistically significant difference 1 d, 5 d, 10 d after treatment （P〉0.05）. Condusion Finasteride exerts no significant effects on bone metabolism and bone mineral density in elder- ly patients with benign prostatic hyperplasia, and the risk of causing osteoporosis is low.
出处
《海南医学》
CAS
2013年第19期2839-2841,共3页
Hainan Medical Journal
关键词
非那雄胺
前列腺增生
骨代谢
骨密度
Finasteride
Prostatic hyperplasia
Bone metabolism
Bone mineral density
